Other Teagasc Research >
Teagasc publications in Biomed Central >
Please use this identifier to cite or link to this item:
|Title: ||In vivo activity of Nisin A and Nisin V against Listeria monocytogenes in mice|
|Authors: ||Campion, Alicia|
Casey, Patrick G.
Cotter, Paul D.
Ross, R Paul
|Issue Date: ||1-Feb-2013|
|Publisher: ||Biomed Central|
|Citation: ||Alicia Campion, Pat G Casey, Des Field, Paul D Cotter, Colin Hill and R Paul Ross. In vivo activity of Nisin A and Nisin V against Listeria monocytogenes in mice. BMC Microbiology 2013, 13:23 doi:10.1186/1471-2180-13-23|
|Series/Report no.: ||BMC Microbiology;vol 13|
|Abstract: ||Background: Lantibiotics are post-translationally modified antimicrobial peptides, of which nisin A is the most extensively studied example. Bioengineering of nisin A has resulted in the generation of derivatives with increased in vitro potency against Gram-positive bacteria. Of these, nisin V (containing a Met21Val change) is noteworthy by virtue of exhibiting enhanced antimicrobial efficacy against a wide range of clinical and food-borne pathogens, including Listeria monocytogenes. However, this increased potency has not been tested in vivo. Results: Here we address this issue by assessing the ability of nisin A and nisin V to control a bioluminescent strain of Listeria monocytogenes EGDe in a murine infection model. More specifically, Balb/c mice were infected via the intraperitoneal route at a dose of 1 × 105 cfu/animal and subsequently treated intraperitoneally with either nisin V, nisin A or a PBS control. Bioimaging of the mice was carried out on day 3 of the trial. Animals were then sacrificed and levels of infection were quantified in the liver and spleen. Conclusion: This analysis revealed that nisin V was more effective than Nisin A with respect to controlling infection and therefore merits further investigation with a view to potential chemotherapeutic applications.|
|Appears in Collections:||Teagasc publications in Biomed Central|
Items in T-Stor are protected by copyright, with all rights reserved, unless otherwise indicated.